AVEO Oncology (AVEO) Announces U.S. Commercial Availability of FOTIVDA for Treatment of Adult Patients With R/R Advanced RCC Ahead of Previous Guidance

AVEO Oncology (AVEO) Prices 6M Share Common Offering at $8/Sh

AVEO Oncology (NASDAQ: AVEO) today announced that it has priced its previously announced underwritten public offering of 6,000,000 shares of its common stock at a price to the public of $8.00 per share. The gross proceeds to AVEO from the offering are expected to be $48.0 million before deducting underwriting discounts and commissions and offering expenses. All of the shares in the... More